bluebird bio, Inc. (NASDAQ:BLUE) Expected to Post Q4 2025 Earnings of ($0.04) Per Share

bluebird bio, Inc. (NASDAQ:BLUE) – Equities research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for shares of bluebird bio in a research note issued to investors on Tuesday, September 24th. Leerink Partnrs analyst M. Foroohar expects that the biotechnology company will earn ($0.04) per share for the quarter. The consensus estimate for bluebird bio’s current full-year earnings is ($1.57) per share.

Several other brokerages have also recently issued reports on BLUE. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of bluebird bio in a report on Thursday, August 15th. Wells Fargo & Company decreased their price target on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. StockNews.com initiated coverage on bluebird bio in a report on Friday. They set a “sell” rating on the stock. Finally, Bank of America decreased their price target on bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.63.

bluebird bio Stock Up 1.4 %

Shares of BLUE opened at $0.50 on Thursday. The stock has a market capitalization of $55.15 million, a price-to-earnings ratio of -0.68 and a beta of 0.75. bluebird bio has a 1 year low of $0.46 and a 1 year high of $5.53. The business’s 50 day simple moving average is $0.77 and its 200-day simple moving average is $0.97. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.93 and a quick ratio of 0.82.

Hedge Funds Weigh In On bluebird bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after buying an additional 1,723,081 shares in the last quarter. Ghisallo Capital Management LLC purchased a new stake in shares of bluebird bio during the 4th quarter worth $4,347,000. Vestal Point Capital LP purchased a new stake in shares of bluebird bio during the 4th quarter worth $2,967,000. HBK Investments L P purchased a new stake in shares of bluebird bio during the 4th quarter worth $2,070,000. Finally, AQR Capital Management LLC lifted its stake in shares of bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after purchasing an additional 1,013,144 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.